Oxford, MS 7/28/2011 (PennyPayDay) --
Bioheart, Inc. (OTC:BHRT) announced today, in a press release, that it has agreed to terms to enter into a license agreement with Airspeed Equity regarding four separate Bioheart patents. BHRT is also under a heavy e-mail marketing campaign initiated about a week ago and has seen volume skyrocket since. As I write, shares of BHRT were up 14 percent at $0.14 per share on volume of more than 1.8 million shares.
The proposed license agreement will have great benefits to both companies: Airspeed will be granted exclusive rights to these patents and all products associated with the patents. Airspeed will pay Bioheart milestone payments and royalties based on sales of potential products. Mike Tomas, President and CEO, stated, "Bioheart is currently focused on our core technology of muscle stem cells for congestive heart failure patients and we are excited about the opportunity to work with Airspeed to bring other Bioheart technologies to market."
The patents include methods of electrical stimulation and biological pacing which are marketed under the MyoStim(TM) product line. Howard Leonhardt, Bioheart's Co-founder and Chief Technology Officer, stated, "The discovery that low voltage electrical stimulation of the heart can both regenerate damaged heart tissue and replace high voltage implantable defibrillators for arrhythmia fibrillation recovery may change the course of care for the more than 30 million patients suffering of heart failure worldwide."
"Bioheart's patents fit perfectly within our medical industry strategy. We are pleased Bioheart selected us to commercialize what we believe will be successful products that can improve people's lives," said Alan Remen, Managing Director, Airspeed Equity.
Bioheart is focused on completing the Phase II/III MARVEL study for chronic heart failure using MyoCell. The product candidate has been in clinical trials since May of 2001 with the goal of commercial approval with the current clinical program. There are approximately 130 more patients needed to complete the randomized, double blinded, placebo controlled MARVEL trial. In part one of the MARVEL trial, the performance of MyoCell was nearly 500% above its primary end point goal of 16 meters improvement in exercise capacity testing. MyoCell treated patients improved 91.7 meters while placebo patients declined 4 meters.
MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.
PennyPayday Free Stock Quotes and Approach to the Stock Market
PennyPayday focuses on bringing penny stocks and small-cap companies from all exchanges, such as (
BHRT), into the spotlight for investors seeking early development opportunities. PennyPayday has quickly become a recognized penny stock site and a top source for investors seeking information and research on today's emerging hot stocks. PennyPayday provides the investing public with stock market daily news, free real-time stock quotes, free stock charts, research for investing, as well as economic stories, videos, and market briefs from a staff of experienced and dedicated financial journalists.
Sign up for our Free Newsletter today, and join the thousands already getting our emails on the hottest stocks to watch.
Disclaimer: Neither
www.PennyPayday.com nor its officers, directors, partners, employees or anyone involved in the publication of this website or newsletters is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. PennyPayday may or may not have been compensated by mentioned companies: (
BHRT). For full disclaimer/disclosure please read
PennyPayday's disclaimer.Distributed by IntelBuilder Social Media Platform
Chicago, IL 10/11/2011 (PennyPayDay) – Tuesday’s smallcap stocks under e-mail promotion campaigns are as follows: Bioheart, Inc. (OTC:BHRT); Nyxio Technologies (PINK:NYXO); Lone Star Gold, Inc. (OTC:LSTG); and SatMAX Corporation (PINK:SATM). These stocks should be pretty volatile today so, be careful if you choose to traded them and always do your own due diligence.
Shawshank, VA 10/6/2011 (PennyPayDay) – Thursday’s smallcap stocks under e-mail promotion campaigns are as follows: Nyxio Technologies (PINK:NYXO); Portage Resources (PINK:POTG); Bioheart, Inc. (OTC:BHRT); and Vringo (Amex:VRNG). These promotional stocks usually have high spikes in volume and are very volatile so, be careful if you choose to trade them and always do your due diligence.
Shawshank, VA 10/4/2011 (PennyPayDay) – Tuesday’s smallcap stocks under e-mail promotion campaigns are as follows: Legend Oil and Gas (OTC:LOGL) and Bioheart, Inc. (OTC:BHRT).
Northern, WI 9/22/2011 (PennyPayDay) – Thursday’s smallcap stocks under e-mail promotion campaigns are as follows: Nyxio Technologies (PINK:NYXO); Legend Oil and Gas (OTC:LOGL); Bioheart (OTC:BHRT); and All American Gold (OTC:AAGC).
Tomahawk, WI 9/21/2011 (PennyPayDay) – Wednesday’s smallcap stocks under e-mail promotion campaigns are as follows: Bioheart, Inc. (OTC:BHRT); All American Gold Corp. (OTC:AAGC); and Nyxio Technologies (PINK:NYXO). All three of these stocks have been under promotion for at least the last few days so, be careful if you decide to trade them as they are always very volatile.
Tomahawk, WI 9/20/2011 (PennyPayDay) – Tuesday’s smallcap promo stocks are as follows: Nyxio Technologies (PINK:NYXO); Bioheart, Inc. (OTC:BHRT); and OriginOil, Inc. (OTC:OOIL). These three stocks should see high volume and volatility today.
Shawshank, VA 9/19/2011 (PennyPayDay) – Bioheart, Inc. (OTC:BHRT) Friday announced, in a press release, it is one of the presenters at the upcoming Cell Therapy Commercialization Summit in Boston from September 19th -- 21st. The three day conference will deliver a comprehensive tool kit for taking your cell therapy product from pre-clinical to commercialization.
Northern, WI 9/15/2011 (PennyPayDay) – Bioheart, Inc. (OTC:BHRT) announced yesterday, in a press release, that they will begin a US clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the FDA to begin a Phase I study in the US. BHRT is also under a pretty aggressive e-mail promotion campaign initiated recently by a third party investor.
Northern, WI 9/14/2011 (PennyPayDay) – Wednesday’s smallcap stocks under e-mail promotion campaigns are as follows: Nyxio Tech Corporation (PINK:NYXO); Bioheart, Inc. (OTC:BHRT); and American Community Development, Inc. (PINK:ACDP).
Tomahawk, WI 8/11/2011 (PennyPayDay) – Bioheart, Inc. (OTC:BHRT) announced yesterday, in a press release, that they have received a 52 week outlook buy rating from biotech focused research firm Prime Equity Research. Kipley J. Lytel, CFA, MBA, senior analyst with New York City-based Prime Equity Research has initiated coverage on Bioheart with a 12-month stock target price and analyst's rating, in a report dated August 2, 2011. The full report includes important disclosures, disclaimers and analyst information. BHRT is also under an e-mail marketing program and as I write, shares were flat at $0.09 per share on moderate volume.
Bioheart, Inc. (OTC:BHRT) announced today that it has entered into an agreement with AnC Bio Holdings, Inc., a South Korean biomedical company, and one of its U.S. agents for a $4 million equity investment. Bioheart has designated proceeds from the investment to advance the current clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases. As I write, shares of Bioheart are down 13 percent at $0.26 per share on volume of 50,000 shares.